PTK2 and neoplasm: Overall, the clinical efficacy of existing FAK inhibitors still fails to meet expectations, and how to ensure high selectivity while reducing off-target effects and toxicities, and making full use of the tumour microenvironment and immune regulatory mechanisms, remains a key issue in the development of this field.